SU
Supriya Lifescience Ltd (SUPRIYA)
₹918.85
Mkt cap
₹7,317 Cr
P/E ratio
36.80
P/B
6.17
Div yield
0.11%
ROE
19.10%
ROCE
25.10%
EPS (TTM)
₹24.97
Book value
₹149
52W range
553–1,053
Sector
Healthcare
Price history
Previous close
Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. [1]
NSE SUPRIYABSE 543434
Health check
Constructive
ValuationFair
ProfitabilityStrong
GrowthHigh
TechnicalsBullish
52-week range
−12.70% from high₹919
₹553+66.05% from low₹1,053
Current
₹918.85
Prev close
₹913.00
Day
+0.64%
Price performance
1D
+0.64%
1W
+14.41%
1M
−0.43%
3M
−3.52%
6M
+47.19%
1Y
+39.75%
YTD
+22.42%
Financials
Revenue, profit & margin
P/E ratio
36.8×
SUPRIYA is 5% above the sector median of 35.1×
SUPRIYA36.8×
Sector median35.1×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 132 | 140 | 140 | 158 | 161 | 166 | 186 | 184 | 145 | 200 | 206 | 277 | 190 | |
| Expenses | 88 | 108 | 99 | 103 | 98 | 101 | 120 | 117 | 93 | 127 | 134 | 179 | 142 | |
| Operating Profit | 44 | 32 | 41 | 56 | 63 | 65 | 66 | 68 | 52 | 73 | 72 | 98 | 47 | |
| OPM % | 34% | 23% | 30% | 35% | 39% | 39% | 36% | 37% | 36% | 36% | 35% | 35% | 25% | |
| Other Income | 3 | 2 | 3 | 2 | 2 | 3 | 2 | 3 | 3 | 3 | 2 | 3 | 3 | |
| Interest | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | |
| Depreciation | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 6 | 6 | 7 | 7 | 8 | 9 | |
| Profit before tax | 43 | 30 | 40 | 53 | 60 | 62 | 63 | 64 | 47 | 68 | 67 | 92 | 41 | |
| Tax % | 33% | 20% | 26% | 31% | 25% | 26% | 25% | 21% | 27% | 26% | 26% | 19% | 41% | |
| Net Profit | 29 | 24 | 30 | 37 | 45 | 46 | 47 | 50 | 35 | 50 | 50 | 74 | 24 | |
| EPS in Rs | 3.54 | 2.97 | 3.70 | 4.59 | 5.55 | 5.73 | 5.81 | 6.26 | 4.32 | 6.27 | 6.17 | 9.22 | 2.99 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −2.69% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 13 Aug '26◦ |
| Earnings day | −2.69% |
| +1 day | −3.63% |
| +5 days | −0.99% |
| +15 days | +4.84% |
| +30 days | — |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Jun 202668.30%Promoter
Promoters68.30%
FIIs6.18%1.02
DIIs5.30%0.40
Public20.21%0.62
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,895.00 | 35.99 | 4,54,674 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,315.00 | 83.00 | 2,47,284 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,914.00 | 83.77 | 1,86,913 | 0.77% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| ZYDUSLIFE | ₹1,156.90 | 23.70 | 1,15,401 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| CIPLA | ₹1,395.00 | 31.49 | 1,12,696 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| LAURUSLABS | ₹1,876.70 | 92.74 | 1,01,400 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,105.00 | 16.17 | 96,254 | 0.86% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| SUPRIYA | ₹909.10 | 36.82 | 7,317 | 0.11% | 24 | −30.90% | 190 | +30.80% | 25.13% |
| Median: 159 Co. | ₹423.00 | 35.07 | 2,282 | 0.08% | 13 | +29.60% | 162 | +18.62% | 15.04% |
Filings
Annual reports6
Concall transcripts51
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025RECAug 2025TranscriptMay 2025PPTMay 2025RECMay 2025TranscriptJan 2025PPTJan 2025RECJan 2025TranscriptNov 2024PPTNov 2024RECNov 2024TranscriptAug 2024
Credit ratings6
Announcements5
Intimation Under Regulation 30 Regarding Letter Dispatched To The Shareholders Of The Company 2 Sep - Annual Report FY26 shared; 18th AGM scheduled for September 24, 2026 via VC/OAVM.Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015. 2 Sep - September 2, 2025 update: GM Sales & Marketing case remains sub judice; no new court order.Announcement under Regulation 30 (LODR)-Newspaper Publication 2 Sep - Copy of Newspaper Public for dispatch of AGM Notice and Annual Report.Business Responsibility and Sustainability Reporting (BRSR) 1 Sep - AGM scheduled for 24 Sep 2026; FY2025-26 annual report and BRSR submitted.Notice Of 18Th Annual General Meeting Of The Company. 1 Sep - 18th AGM on Sept 24, 2026; final dividend Re. 1 per share, record date Sept 4.